BioMarin Pharma (BMRN) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $54.38 -1.82%
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
CMTL, EQBK, BLK, More
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
CMTL, EQBK, BLK, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.32), $0.14 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $400 million versus the consensus estimate of $389.69 million.
- 2019 Full-Year Financial Guidance unchanged
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- Goldman Sachs (GS) Reiterated at Market Perform by Citizens as View of Earnings Opportunity Raised
- Barclays Starts Alcoa (AA) at Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
